Navigation Links
Migenix to Present Celgosivir Phase II Hepatitis C Results at,Digestive Disease Week 2007

VANCOUVER and SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases will make a presentation of results from a recent hepatitis C Phase II combination therapy study (see April 11, 2007 press release) in a non-responder patient population at Digestive Disease Week (DDW) 2007 being held in Washington, DC May 19-24, 2007. Dr. Kelly Kaita, the Director of the Viral Hepatitis Investigative Unit (VHIU) at the Health Sciences Centre, University of Manitoba and a lead investigator in the MIGENIX Phase II study will make the presentation.

The presentation entitled: "Phase II Study of Celgosivir in Combination with Peginterferon alfa-2b and Ribavirin in Chronic Hepatitis C Genotype-1 Non-responder Patients" (Abstract # 324227) will be made on Monday, May 21, at 2:45 p.m. (EDT) in Room 206 of the Washington Convention Center. Additionally on May 20, 2007 Dr. Kaita and AnnKatrin Petersen, M.D., Vice President, Clinical Development of MIGENIX will participate in a DDW news conference highlighting progress in new and evolving areas of chronic hepatitis C therapy including celgosivir. A copy of the presentation and the related Abstract will be available at www.migenix.com following the presentation.

Research being presented at Digestive Disease Week 2007 analyzes advancements in the diagnosis of hepatitis C and therapies available to patients who suffer from the disease. DDW is the largest international gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Digestive Disease Week is considered the largest and most prestigious meeting in the world for the gastrointestinal professional. Every year DDW attracts more than 16,000 physicians, researchers and academics from around the world.

About Celgosivir (MX-3253)< /p>

Celgosivir is an oral alpha-glucosidase I inhibitor and is currently the only anti-HCV drug in clinical development that acts on host-directed glycosylation. In preclinical studies, celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or without ribavirin) and other drugs in development for the treatment of HCV (e.g. polymerase inhibitors) and therefore has the potential to be included as part of multiple combination approaches to improve efficacy in anti-HCV therapy.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at www.migenix.com.

    "Art Ayres"

    -----------

    Arthur J. Ayres, CA.

    Sr VP Finance & CFO


    The Toronto Stock Exchange has not reviewed and does not accept

    responsibility for the adequacy or accuracy of this release.


CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233, ; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, aayres@migenix.com Theproteam@aol.com

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233,; Dian Griesel, Ph.D., Investor Relations Group, Tel:(212) 825-3210, aayres@mi genix.com Theproteam@aol.com

Ticker Symbol: (Toronto:MGI.),(NASDAQ-OTCBB:MGIFF)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 - ... in Personalized Medicine and Cancer Therapy. - European ... Diagnostic Testing Markets. - Key Diagnostic Testing Markets. ... Molecular Diagnostics in Genetic Testing. - Molecular Diagnostics ... - Over-the-Counter Diagnostic Products World Markets. - ...
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016  Kindred Biosciences, ... on saving and improving the lives of pets, today ... Section of the New Animal Drug Application (NADA) for ... pivotal field study (KB0120) of Zimeta for the control ... the Company. --> --> ...
(Date:2/11/2016)... -- NOIT™ Research LLC, a private, leading-edge autism research group, ... assist needy families in obtaining one of its special ... 10, 2016 and March 31, 2016, the company will ... is an auditory stimulus that plays a key role ... Beth Shier , NOIT Research director. "The ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... Sun City is the place to be on March 3rd to learn about the latest ... hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting advancements will be presented ... addition, prizes will be given away and light refreshments will be served. , As ...
(Date:2/13/2016)... ... ... Many individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and increased ... has delved into this niche allowing those giving up their beloved pasta a chance ... grams of protein and only 7 grams of carbohydrates per 50 gram serving--a ratio ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly released ... visualization technology should be used to ensure patient safety when placing an IV ... Standards mandate the use of vein visualization technology in patients with difficult venous ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or ... groom themselves to perfection, go out of their way to be romantic, and may ... take a look at any online dating profile. , A recent study from ...
(Date:2/12/2016)... San Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... of love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. ... in fact a love story, the love of a Buddhist teacher for teaching and ...
Breaking Medicine News(10 mins):